Code
365O2312
Duration
01 October 2011 → 30 September 2013
Funding
Funding by bilateral agreement (private and foundations)
Promotor
Research disciplines
-
Medical and health sciences
- Public health care
- Public health sciences
- Public health services
Keywords
resistance
colon cancer
carcinoma-associated fibroblast
tumor environment
Project description
Anti-EGFR therapy (cetuximab or panitumumab) is a well known targeted therapy in metastatic colorectal cancer (mCRC). This project will search for insights in stromal-dependent delivery of signalling ligands that are associated with upfront resistance to anti-EGFR therapy or mechanisms of acquired resistance to anti-EGFR therapy; and to find biomarkers identifying patients at high risk for therapy resistance.